Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Peter Blume-Jensen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 75
- Beta
- 1.86
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -1.55
Financials
Net Income
$-17.96MEBITDA
$-17.56MFree Cash Flow
$-14.95MEPS (diluted)
$-0.43Shares Outstanding (diluted)
41.84M+224.1%Operating Expenses
$18.67MCash & Debt
$89.96MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-77.91M | $-2.02 |
| 2024 | $0.00 | $-80.56M | $-2.10 |
| 2023 | $0.00 | $-60.39M | $-2.74 |
| 2022 | $0.00 | $-31.17M | $-1.42 |
| 2021 | $0.00 | $-16.24M | $-1.26 |
| 2020 | $0.00 | $-5.31M | $-0.41 |
Valuation
ACRVhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120Social Signal Score
Mentions (1)
- Newszacks.com·6h ago·Positive
Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy Does Acrivon Therapeutics, Inc. (ACRV) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗
Earnings
Thu, Nov 12(in 3 months)
Consensus estimate $-0.45 per share
Typical surprise +10.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.43 vs $-0.50beat
- Wed, May 13$-0.49 vs $-0.49beat
- Thu, Mar 19$-0.49 vs $-0.49beat
- Thu, Nov 13$-0.47 vs $-0.57beat
- Wed, Aug 13$-0.55 vs $-0.57beat
- Wed, May 14$-0.51 vs $-0.57beat
Estimates and results for ACRV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ACRV officers and directors.
- Bought
- $114k
- Sold
- $3.8m
3 trades
13 trades
- Peterson Katharinesold
- Miller Marysold
- Gamelin Ericksold
- Devroe Ericsold
- Blume-jensen Petersold
- Blume-jensen Petersold
- Levy Adam D.sold
- Miller Marysold
84 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.